Original Article

Effect of thrombolytic therapy on the patterns of post myocardial infarction ventricular septal rupture

Sunil Kumar Srinivasa,⁎, Bharathi Sunilb, Prabhavathi Bhatc, Cholenahally Nanjappa Manjunath

⁎ Department of Cardiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India
bac Department of Anesthesiology, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India

Article history:
Received 28 July 2016
Accepted 19 March 2017
Available online 1 April 2017

Keywords:
Ventricular septal rupture
Myocardial infarction
Thrombolysis
Echocardiography

Abstract

Objectives: Ventricular septal rupture (VSR) is a rare but feared complication after myocardial infarction (MI). The objective of this study was to investigate the effects of thrombolytic therapy on the patterns of VSR following MI.

Methods: 30 consecutive patients admitted to a single tertiary level cardiac hospital with a diagnosis of acute MI and developed VSR in the hospital were included. The effect on thrombolytic therapy on the formation of VSR and its clinical outcome was studied.

Results: Out of 30 patients, 15 patients received thrombolytic therapy. 10 received early (<12 h) and 5 received late (>12 h). The median time to post MI VSR formation was significantly shorter in thrombolysis group compared to non-thrombolysis group at 1 vs 3 days (p = 0.026). The median time for VSR formation was shorter in early thrombolysis group compared to late thrombolysis group at 1 vs 3 days (p = 0.022). There was no difference between late and no thrombolytic therapy (3 vs 3 days, p = 0.672). There was no significant difference in the mortality between thrombolytic and no thrombolytic therapy (p = 0.690). Patients treated medically had a significantly higher mortality compared to patients treated surgically (p = 0.005).

Conclusion: Thrombolytic therapy results in an earlier presentation of VSR after MI. This earlier presentation may be due to reduction in the number of patients developing late VSR after thrombolytic therapy, while the number of patients developing an early VSR remaining unaffected. Despite improvements in medical therapy and percutaneous and surgical techniques, mortality with this complication remains extremely high.

© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1 Introduction

Ventricular septal rupture (VSR) is a rare but often fatal complication of acute myocardial infarction (MI). In prethrombolytic era the reported incidence of post MI VSR was 1%–2%.1,2 However introduction of reperfusion therapy like thrombolysis and primary percutaneous intervention (PCI) has significantly reduced its incidence with only 0.2% reported in the GUSTO-I trial.3 Several factors have been identified to be associated with an increased risk of developing a post MI VSR like female sex, hypertension, anterior MI, prior angina, and increasing age.1,4 In the prethrombolytic era, outcomes after the development of VSR were extremely poor, with an in-hospital mortality of 45% in surgically treated patients and 90% in those managed medically.5–7 Factors predicting increased mortality include cardiogenic shock, longer duration of bypass, previous infarct, right heart compromise, inferior myocardial infarction and size of infarct.8,9,10–15

In prethrombolytic era it was reported that VSR typically occurs within the first week of MI with a mean time from symptom onset of 3–5 days.16,17 In thrombolytic era studies have given conflicting evidence regarding the time of onset of VSR after MI. In GUSTO-I trial the mean time of development of VSR after thrombolysis was 1 day.3 However in the SHOCK trial there was no difference in the time of development of VSR between the thrombolytic and nonthrombolytic groups.16

http://dx.doi.org/10.1016/j.ihj.2017.03.007
0019-4832/© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The aim of the present study was to evaluate the difference in the time of onset of VSR after MI between thrombolytic and non-thrombolytic patients admitted to a single tertiary care cardiac hospital. Furthermore we sought to study the factors associated with the increased mortality in patients who develop VSR.

2. Methods

In this prospective study done between January 2012 to December 2012, 30 patients with diagnosis of post MI VSR were included. Enrolment criteria included patients presenting with chest pain lasting ≥20 min and satisfying the World Health Organization criteria of acute MI and developing VSR within the hospital. Exclusion criteria included patients who had developed VSR outside the hospital and referred for further management. Informed consent was taken from all patients. Ethical clearance was taken before conducting the study.

The time of onset of chest pain was considered as the time of onset of the acute myocardial infarction. Acute myocardial infarction was diagnosed using the standard 12 lead electrocardiogram and cardiac enzyme (World Health Organization criteria). The time from onset of myocardial infarction to thrombolysis was separated into early (<12 h) or late (>12 h); this was the time from initial onset of pain to the time when the patient received thrombolysis. The time of onset of the VSR was assumed to coincide with the abrupt onset of symptoms and new murmur as documented in the patient’s clinical record. The diagnosis of VSR was confirmed with Trans thoracic echocardiography in all cases. Patients were divided into two groups- thrombolytic group and non-thrombolytic group. The thrombolytic group was further divided into patients receiving thrombolysis within 12 h and those receiving thrombolysis 12 h or later. Streptokinase was used as thrombolytic agent in all the patients. All patients were analyzed for risk factors, demographics, clinical profile, treatment and prognosis.

Table 1
Baseline clinical characteristics.

| Variable                  | Total (n = 30) | Thrombolysis group (n = 15) | Non Thrombolysis group (n = 15) |
|---------------------------|---------------|----------------------------|---------------------------------|
| Age in years (Mean ± SD)  | 63.4 ± 9.8    | 66.07 ± 6.1                | 60.73 ± 12.1                   |
| Sex (Male)                | 18 (60%)      | 10 (66.6%)                 | 8 (53.3%)                      |
| Risk factors              |               |                            |                                 |
| Diabetes                  | 15 (50%)      | 8 (53.3%)                  | 7 (46.6%)                      |
| Hypertension              | 12 (40%)      | 7 (46.6%)                  | 8 (53.3%)                      |
| Dyslipidemia              | 5 (33.3%)     | 3 (20%)                    | 2 (13.3%)                      |
| Smoking                   | 10 (33.3%)    | 5 (33.3%)                  | 5 (33.3%)                      |
| History of angina         | 4 (13.3%)     | 1 (6.6%)                   | 3 (20%)                        |
| Family history            | 4 (13.3%)     | 3 (20%)                    | 1 (6.6%)                       |
| Old MI                    | 3 (10%)       | 1 (6.6%)                   | 2 (13.3%)                      |
| Presentations             |               |                            |                                 |
| AWMI                      | 18 (60%)      | 8 (53.3%)                  | 10 (66.6%)                     |
| IWMI                      | 12 (40%)      | 7 (46.6%)                  | 5 (33.3%)                      |
| Ejection fraction         | 44.07 ± 6.4   | 45.87 ± 7.1                | 42.27 ± 5.1                    |
| CK-MB (Mean ± SD)         | 121.5 ± 139.84| 82.47 ± 76.4               | 160.53 ± 177.1                 |
| Treatment                 |               |                            |                                 |
| Heparin                   | 27 (90%)      | 13 (86.6%)                 | 14 (93.3%)                     |
| Aspirin                   | 30 (100%)     | 15 (100%)                  | 15 (100%)                      |
| Clopidogrel               | 29 (96.6%)    | 15 (100%)                  | 14 (93.3%)                     |
| Beta blocker              | 14 (46.6%)    | 8 (53.3%)                  | 6 (40%)                        |
| ACE Inhibitor             | 15 (50%)      | 9 (60%)                    | 6 (40%)                        |
| Diuretics                 | 15 (50%)      | 7 (46.6%)                  | 8 (53.3%)                      |
| nesotropes                | 26 (86.6%)    | 13 (86.66%)                | 13 (86.66%)                    |
| NTG                       | 3 (10%)       | 1 (6.6%)                   | 2 (13.3%)                      |
| Examination               |               |                            |                                 |
| Pulse >100                | 19 (63.3%)    | 9 (60%)                    | 10 (66.6%)                     |
| Systolic BP < 90          | 19 (63.3%)    | 11 (73.33%)                | 8 (53.33%)                     |
| Raised JVP                | 22 (73.33%)   | 10 (66.66%)                | 12 (80%)                       |
| Killip I                  | 11 (41.33%)   | 9 (60%)                    | 4 (26.6%)                      |
| Killip II                 | 10 (33.33%)   | 3 (20%)                    | 7 (46.6%)                      |
| Killip III                | 2 (6.6%)      | 1 (6.66%)                  | 1 (6.6%)                       |
| Killip IV                 | 5 (16.6%)     | 2 (13.3%)                  | 3 (20%)                        |
| Urea (mg/dl)              | 58.40 ± 49.59 | 61.67 ± 52.79              | 55.13 ± 47.81                  |
| Creatinine (mg/dl)        | 1.35 ± 0.72   | 1.24 ± 0.51                | 1.45 ± 0.89                    |
| IABP                      | 19 (63.3%)    | 11 (73.33%)                | 8 (53.33%)                     |
| Total occlusion of infarct artery | 21 (70%) | 9 (60%) | 12 (80%) |
| 30 days mortality         | 16 (53.33%)   | 8 (53.33%)                 | 8 (53.33%)                     |
| 1 year mortality          | 21 (70%)      | 11 (73.33%)                | 10 (60%)                       |

MI: Myocardial infarction; AWMI: Anterior wall myocardial infarction; IWMI: Inferior wall myocardial infarction; NTG: Nitroglycerin; JVP: Jugular venous pulse; IABP: Intra aortic balloon pump.
Mean follow up was 1 year and 100% complete. It was at regular intervals with clinical visits or telephone interviews.

3. Statistical analysis

All statistical analysis was performed using SPSS statistical software (version 16.0, SPSS Inc., Chicago, Illinois). Categorical variables are expressed as counts and percentage. Continuous variables are expressed as mean ± SD or median ± interquartile range (25th percentile to 75th percentile) as appropriate. Categorical variables, expressed as percentages, were analyzed with chi-square or Fisher’s exact test. Continuous variables were analyzed using two-tailed t-test or Mann–Whitney U test. Univariate factors with p value < 0.25 were analyzed using binary logistic regression analysis. A two tailed p-value less than 0.05 was used to indicate statistical significance.

4. Results

There were 30 eligible patients with the diagnosis of post MI VSR who had developed the complication in the hospital. The baseline clinical demographics of these patients are presented in Table 1. There was no significant difference between the two groups with respect to risk factors, clinical profile or treatment except for the time of VSR formation which was significantly less in thrombolysis group. Out of total 30 patients, 12(40%) of them were female, the mean (SD) age was 63.4 (9.8) years, 18 (60%) of them had a history of angina, and 12 (40%) of them had hypertension. All of these factors were previously found to be significantly associated with VSR. 18 had apical VSR and 12 has basal VSR. Size of the VSR varied from 4 mm to 16 mm with average of 8 mm in diameter. 3 (10%) of them had old MI, 20 (66.6%) of them had pulse >100 beats/minute, 19 (63.3%) of them had blood pressure (BP) ≤ 90 mm Hg and 12(40%) had inferior wall MI; all these were previously found to be associated with increased mortality. 7 of them had biventricular failure. In this study, pulse >100 beats/min and BP ≤ 90 mm Hg were found to be associated with increased mortality in univariate analysis. However multivariate analysis showed that it was not statistically significant. There was no statistically significant difference in the mortality between thrombolysis and no thrombolysis group (p = 0.690). Even though it was not statistically significant mortality tended to be higher in patients with biventricular failure. Mortality data of the patients are summarised in Table 2.

Regarding effect of thrombolysis on development of VSR, 15 (50%) patients received thrombolytic therapy, 10 of them received early (<12 h after MI) and 5 of them received late (>12 h) thrombolytic therapy. The other 15 were not given thrombolysis due to late presentation. The data for time to VSR formation is detailed for each group in Table 3. The median time for development of VSR in patients with thrombolytic therapy was significantly shorter than in patients without thrombolytic therapy (1 vs. 3 days, p = 0.026). Significant difference was also found between patients who were thrombolysed early (median = 1 day, range 1-4 days) compared to patients with late thrombolysis (median = 3 days, range 2-4 days p = 0.022). There was no statistically significant difference in the development of VSR between late (median = 3 days, range 2-4 days) and no thrombolysis group (median = 3 days, range 1-8 days, p = 0.672). Table 4 illustrates the effect of thrombolysis on the time of development of VSR.

Angiographically 21 (70%) patients had total occlusion of infarct related artery (13 Left anterior descendening artery (LAD), 7 Right coronary artery and 1 left circumflex artery). Out of 18 LAD arteries 11 were wraparound arteries. 14 (46%) had single vessel, 10 had double vessel (33.3%) and 6 (20%) had triple vessel disease. 15 (50%) patients underwent surgical intervention. 14 (93.3%) of them underwent both coronary artery bypass surgery (CABG) and VSR repair, and the remaining 1 (6.6%) patient underwent VSR repair alone. Timing of the surgery was decided by the surgeon and mainly based on the clinical condition of the patient. The median day of surgery from the onset of VSR was 3 days (Range 1-42 days). There were 2 (13.3%) peri-operative deaths. Mortality at 30 days was 20% (n = 3) and at 1 year 46.66% (n = 7). 15 patients were treated medically. Patients treated medically were significantly older and had advanced heart failure compared to those treated surgically. The 30 days mortality in this group of patients was 86.66% (n = 13) and at 1 year it was as 93.3% (n = 14). There was a significant difference in mortality between medically treated and surgically treated patients, with very high mortality in the former group (p = 0.005). Intracavitary balloon pumps (IABP) was inserted in 19(63.3%) patients. Surgical data is summarised in

| Risk factor          | Number | Number (%) of deaths | Univariate analysis P value | Multivariate analysis P value (CI) |
|----------------------|--------|-----------------------|-----------------------------|-----------------------------------|
| Pulse                |        |                       |                             |                                   |
| <100/min             | 10     | 4 (40%)               | 0.011                       | 0.082 (0.78-56.28)                |
| >100/min             | 20     | 17 (85%)              |                             |                                   |
| Systolic BP          |        |                       |                             |                                   |
| >90 mm Hg            | 11     | 4 (36.36%)            | 0.011                       | 0.082 (0.78-56.28)                |
| ≤ 90 mm Hg           | 19     | 17 (89.47%)           |                             |                                   |
| Raised JVP           |        |                       |                             |                                   |
| < 3 cm               | 21     | 16 (76.19%)           | 0.283                       | –                                 |
| > 3 cm               | 09     | 05 (55.55%)           |                             |                                   |
| Location of MI       |        |                       |                             |                                   |
| AWMI                 | 18     | 12 (66.66%)           | 0.689                       | –                                 |
| IWMI                 | 12     | 9 (75%)               |                             |                                   |
| Thrombolysis         |        |                       |                             |                                   |
| Yes                  | 15     | 11 (73.33%)           | 0.756                       | –                                 |
| No                   | 15     | 10 (80%)              |                             |                                   |

BP - Blood pressure; JVP- Jugular venous pressure; MI- myocardial infarction; AWMI- Anterior wall MI; IWMI- Inferior wall MI
Table 3
Patients numbers in terms of days from myocardial infarction to VSR and thrombolytic therapy

| Number of days from MI to VSR (n = 15) | No thrombolyis | Early thrombolyis (n = 10) | Late thrombolyis (n = 5) | Total |
|--------------------------------------|----------------|---------------------------|--------------------------|-------|
| 1                                    | 1              | 9                         | 0                        | 10    |
| 2                                    | 2              | 0                         | 1                        | 3     |
| 3                                    | 7              | 1                         | 3                        | 11    |
| 4                                    | 1              | 0                         | 1                        | 2     |
| 5                                    | 0              | 0                         | 0                        | 0     |
| 6                                    | 2              | 0                         | 0                        | 2     |
| 7                                    | 1              | 0                         | 0                        | 1     |
| 8                                    | 1              | 0                         | 0                        | 1     |
| Total = 15                           | Total = 10     | Total = 5                  | Total = 30               |       |

Table 4
Influence of Thrombolysis on time to VSR formation.

| Median time to VSR formation(days) | Thrombolysis (n=15) | No Thrombolysis (n=15) | P value |
|------------------------------------|---------------------|------------------------|---------|
| Median ± SD (range)                | 3.00 ± 2.0 (1–8)    | 3.00 ± 2.0 (1–8)       | 0.003   |
| Median ± SD (range)                | 1.00 ± 1.08 (1–4)   | 1.00 ± 1.08 (1–4)      |         |
| Median ± SD (range)                | 1.00 ± 0.62 (1–3)   | 1.00 ± 0.62 (1–3)      |         |
| Median ± SD (range)                | 3.00 ± 0.7 (2–4)    | 3.00 ± 0.7 (2–4)       | 0.003   |

Table 5
Surgical data: Number (%).

| Treatment                          | Surgical (n = 15) | Medical (n = 15) |
|------------------------------------|------------------|-----------------|
| Surgical                           | 15 (50%)         | 15 (50%)        |
| Surgical details                   |                   |                 |
| VSR repair alone                   | 1(6.6%)           |                 |
| VSR repair + CABG                  | 14 (93.33%)       |                 |
| IABP used                          | 19 (63.33%)       |                 |
| Immediate post op death            | 2 (13.33%)        |                 |

VSR-ventricular septal rupture; CABG-Coronary artery bypass grafting; IABP-Intra-aortic balloon pump.

Table 6
Influence of Surgery on Mortality.

| Mortality                        | Surgery (n = 15) | Medical (n = 15) | P value |
|----------------------------------|------------------|-----------------|---------|
| Mortality at 30 days             | 3(20%)           | 13 (86.66%)     | <0.001  |
| Mortality at 1 year              | 7(46.66%)        | 14 (93.33%)     | 0.005   |

5. Discussion

VSR remains an infrequent but often fatal complication of acute myocardial infarction. The use of thrombolytic agents have reduced the incidence from 1%-2%.1,2 in the prethrombolytic era to 0.2%3 in the thrombolytic era. In the prethrombolytic era VSR occurred most often in the first week of AMI, typically three to five days after onset of symptoms.3,8,9 Few studies with the use of thrombolytic agents have shown that the time of formation of VSR has reduced to 1 day.4,5 In GUSTO I trial the mean time from infarction to development of VSR was found to be 1 day.5 Becker and colleagues also reported similar findings.10,13 Rhydwen et al. showed that the median time for VSR formation was 1 day in thrombolytic patients compared to 5.5 days in patient without thrombolysis.15 They also showed that patients treated with early thrombolysis (<12 h) developed VSR early compared to patients with late thrombolysis (>12 h). However in SHOCK trial there was no difference in the time of development of VSR between the thrombolytic and non thrombolytic groups.16 In the present study we show that time to VSR formation in acute MI after thrombolytic therapy is significantly shorter. We also show that late thrombolytic therapy does not appear to have this effect. This raises the possibility that only early thrombolytic therapy accelerates the time from MI to VSR. Similar to Rhydwen et al. we used 12 h from the onset of pain to thrombolytic therapy as cut off between early and late groups. However all patients received thrombolysis within 8 h of the onset of symptoms. The median time to VSR formation in patients without thrombolysis was 3 days similar to studies quoted from prethrombolytic era.

Several mechanisms have been proposed for acceleration of post MI VSR formation in thrombolytic patients. Thrombolytic therapy appears to reduce the overall incidence of cardiac rupture,3,4 probably by restoring vessel patency, salvaging myocardium, and preventing on going infarct expansion resulting in a decreased incidence of late myocardial rupture.3,8,18-20 The GUSTO investigators analysis of mortality within one day of thrombolytic therapy, however, shows that deaths within four hours of treatment were not influenced by the establishment of arterial patency, that patients were more likely to have severe cardiac dysfunction and larger infarcts.21 Patients, who develop a post myocardial infarction VSR, although unlikely to die this early, are also more likely to have an occluded artery and larger infarct.3,8,15,20,22,25 Thus it is likely that in patients who develop an early post Myocardial infarction VSR thrombolytic therapy is unlikely to salvage already necrosed myocardium and have little influence on the incidence or time of development of early VSRs. Overall therefore there is probably a reduction in the number of patients developing a late VSR while there is retension, or slight increase in the number of patients developing an early VSR. This would move the median and mean time of post-myocardial infarction VSR earlier, giving an apparent acceleration of events.

Another mechanism proposed is that reperfusion following thrombolysis may potentially promote haemorrhage and dissection in the myocardium, thus accelerating the risk of rupture.24 Rupture was also seen within one to two days in the smaller group of patients treated with primary angioplasty.24 Reperfusion injury
has been shown to increase infarct size in animal models, which could increase the incidence and decrease the time to post-myocardial infarction cardiac rupture.\textsuperscript{25–27} Against this are the findings that the majority of post-myocardial ruptures occur when the infarct related artery is occluded.\textsuperscript{3,8,15,20,22,23} The GUSTO investigators also provided no evidence that arterial patency leads to reperfusion injury in terms of cardiac rupture or left ventricular dysfunction.\textsuperscript{21} Finally, thrombolytic agents increase the circulating and infarct levels of plasmin, a proteolytic enzyme capable of degrading collagen.\textsuperscript{28} Independently of vessel patency, probably resulting in increased proteolytic activity at the infarct site. This could reduce collagen locally, which is implicated in infarct expansion.\textsuperscript{29} This again could accelerate the time to and increase the incidence of post-MI VSRs. The exact role of this mechanism on the timing of post MI VSR formation is unclear.

Thrombolytic therapy increases the incidence of haemorrhagic infarct independently of vessel patency with the haemorrhagic area almost exclusively confined to the infarct area and not associated with infarct expansion.\textsuperscript{30–32} Although thrombolytic therapy increases the number of infarcts with haemorrhage, the incidence of myocardial rupture, is probably not significantly affected as nearly all myocardial ruptures occur in the small percentage of infarcts that have extensive haemorrhage in any case. It is therefore unlikely that post MI VSR is a haemorrhagic complication of thrombolytic therapy. Indeed cardiac rupture events are not increased in patients receiving concurrent anticoagulants along with thrombolytic therapy.\textsuperscript{33} Our study also supports this, as late thrombolytic therapy appeared to have no influence on the time from myocardial infarction to VSR. It would still seem reasonable, however, to hypothesise that the fibrinolytic state induced by thrombolytic therapy could accelerate and slightly increase the possibility of rupture in large haemorrhagic infarcts. The required number of cases to demonstrate this, however, would probably need to be larger than reported to date. Our angiographic data, consistent with previous studies, show that patients who develop VSRs after acute MI are more likely to have total occlusion of the infarct artery.\textsuperscript{1} This suggests that the pathophysiology of acute VSR involves sudden, severe ischemia, leading to extensive myocardial necrosis, and that patients who do not reperfuse with thrombolysis are at increased risk of mechanical complications. This group of patients also had more extensive coronary disease and poor LV function.

VSR is associated with extremely high mortality even in thrombolytic era despite improvements in medical therapy and percutaneous and surgical techniques.\textsuperscript{3} In our study overall 30 days mortality was 53.5% and 1 year mortality was 70%. This suggests that if the patient survives the initial admission, the long term prognosis is relatively good. Previous studies suggested that patients with old MI, inferior infarct, pulse >100/min and BP <90 mm Hg are associated with high mortality.\textsuperscript{3,4,8–13} The reasons proposed for worse outcome with inferior infarct is that, it is associated with complex VSRs and located in the inferobasal portion of the septum and therefore were more difficult to approach surgically.\textsuperscript{3} Anterior infarcts were more commonly associated with simple, through-and-through defects in the apical septum, which tend to be more easily repaired. Our study did not show any difference in mortality, probably due to improvement in surgical techniques over the years. However patients with tachycardia and hypotension had trend towards high mortality suggesting extensive myocardial damage and poor LV function associated with this group of patients. Thrombolysis was not associated with increased mortality contrary to some studies which suggested that it may increase the mortality in patients with VSR.\textsuperscript{4,17}

6. Study limitations

This was a single center nonrandomized study, so it has its inherent limitations. The number of patients involved even though comparable to other studies, is still relatively small with limited statistical power. The incidence of VSR was not calculated because patients who developed VSR outside the hospital and referred for further management were not included in the study. Only Trans thoracic echocardiography was used for diagnosis of VSR. Trans oesophageal echocardiography was not used as the diagnosis was clear in transthoracic images and most of these patients were sick. Pulmonary capillary wedge pressure was not checked in any of the patients. Streptokinase was the only thrombolytic agent used in all patients. We do not know the effect of other thrombolytic agents on the development of VSR. Finally trans catheter closure of VSR was not attempted in any of the patients. We do not know the effect of this procedure on mortality of these high risk patients.

7. Conclusions

Thrombolytic therapy is known to decrease the incidence of VSR following acute myocardial infarction. However it results in an earlier presentation of VSR compared to patients without thrombolytic therapy. The acceleration in the VSR formation after thrombolytic therapy would not appear to be a reperfusion injury or haemorrhagic complication. There is a reduction in the number of patients developing a late post MI VSR after thrombolytic therapy, while the number of patients developing an early post MI VSR remains the same or is not reduced to the same degree. This moves the mean and median time from MI to VSR earlier and this is the most likely mechanism for the apparent acceleration of events leading to post MI VSR formation in patients treated with thrombolytic therapy. Thus this earlier presentation appears to be due to the positive impact of thrombolytic therapy in reducing the incidence of late post-MI VSRs. Most of these patients have totally occluded culprit arteries. Outcome in these patients remains extremely poor, with a mortality rate of 46% in patients undergoing surgical repair and 93% in those treated medically. More effective ways to predict, prevent, and treat this devastating complication are needed.

References

1. Topaz O, Taylor AL. Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management. Am J Med. 1992;93:683–688.
2. Heimiller R, Jacobs M, Daggett WM. Surgical management of postinfarction ventricular septal rupture. Ann Thorac Surg. 1986;41:683–691.
3. Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation. 2000;101:27–32.
4. Becker RC, Hochman JS, Cannon CP, et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol. 1999;33:479–487.
5. Davies RH, Dawkins KD, Skillington PD, et al. Late functional results after surgical closure of acquired ventricular septal defect. J Thorac Cardiovasc Surg. 1993;106:592–598.
6. Jones MT, Schofield PM, Dark JF, et al. Surgical repair of acquired ventricular septal defect: determinants of early and late outcome. J Thorac Cardiovasc Surg. 1987;93:680–686.
7. Bolooki HB. Emergency cardiac procedures in patients in cardiogenic shock due to complications of coronary artery disease. Circulation. 1989;79(Suppl. I):I–137–1–148.
8. Edwards BS, Edwards WD, Edwards JE. Ventricular septal rupture complicating acute myocardial infarction: identification of simple and complex types in 57 autopsied hearts. Am J Cardiol. 1984;54:1201–1205.
9. Moore CA, Nygaard TW, Kaiser DL, et al. Postinfarction ventricular septal rupture: the importance of location of infarction and right ventricular function in determining survival. Circulation. 1986;74:45–55.
10. Becker RC, Gore JM, Lambrew C, et al. for the national registry of myocardial infarction participants: a composite view of cardiac rupture in the United States national registry of myocardial infarction. J Am Coll Cardiol. 1996;27:1321–1326.
11. Feneley MP, Chang VP, O'Rourke MF. Myocardial rupture after acute myocardial infarction. Ten year review. J Br Heart. 1983;49:550–556.
12. Held AC, Cole PL, Lipton B, et al. Rupture of the interventricular septum complicating acute myocardial infarction: a multicenter analysis of clinical findings and outcome. Am Heart J. 1988;116(5 pt 1):1330–1336.
13. Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol. 1995;25:1063–1068.
14. Di Summa M, Actis Dato GM, Centofanti P, et al. Ventricular septal rupture after a myocardial infarction: clinical features and long term survival. J Cardiovasc Surg (Torino). 1997;38:589–593.
15. Cummings RG, Reiner KA, Califf R, et al. Quantitative analysis of right and left ventricular infarction in the presence of postinfarction ventricular septal defect. Circulation. 1988;77:33–42.
16. Menon V, Webb JC, Hills LD, et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries in cardiogenic shock? J Am Coll Cardiol. 2000;36:1110–1116.
17. Rydewen GR, Charmian S, Schofield PM. Influence of thrombolytic therapy on the patterns of ventricular septal rupture after acute myocardial infarction. Postgrad Med J. 2002;78:408–412.
18. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753–770 ISIS-3 (Third International Study of Infarct Survival) Collaborative Group [see comments].
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682 The GUSTO investigators [see comments].
20. Lewis AJ, Burchell HB, Titus JL. Clinical and pathologic features of postinfarction cardiac rupture. Am J Cardiol. 1989;23:43–53.
21. Leimann NS, White HD, Ohman EM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction The importance of early reperfusion. The GUSTO Investigators. Circulation. 1994;90:2638–2665 The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [see comments].
22. Chierici EC, de Swart H, Dijkman LW, et al. Myocardial rupture after myocardial infarction is related to the perfusion status of the infarct-related coronary artery. Am Heart J. 1995;129:644–650.
23. Skehan JD, Carey C, Norrell MS, et al. Patterns of coronary artery disease in post-infarction ventricular septal rupture. Br Heart J. 1989;62:268–272.
24. Poulsen SH, Præstholm M, Munk K, Wierup P, Egebøl H, Nielsen-Kudsk JE. Ventricular septal rupture complicating acute myocardial infarction: clinical characteristics and contemporary outcome. Ann Thorac Surg. 2008;85:1591–1596.
25. Fabr A, Kolodgie FD, Jenkins M, et al. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J Am Coll Cardiol. 1993;21:1245–1253.
26. Ambrosio G, Weissman HF, Mannis JA, et al. Progressive impairment of regional myocardial perfusion after initial restoration of posts ischemic blood flow. Circulation. 1989;80:1846–1861.
27. Dreyer WJ, Michael LH, West MS, et al. Neutrophil accumulation in ischemic canine myocardium Insights into time course, distribution, and mechanism of localization during early reperfusion. Circulation. 1991;84:400–411.
28. Peuhkurinen KJ, Risteli L, Melkko JT, et al. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation. 1991;83:1969–1975.
29. Whitaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial infarct expansion. Circulation. 1991;84:2123–2134.
30. Fujisawa H, Onodera T, Tanaka M, et al. A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase. Circulation. 1986;73:749–757.
31. Gertz SD, Kragel AH, Kalan JM, et al. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Am J Cardiol. 1990;66:904–909.
32. Mathey DG, Schofer J, Kuck KH, et al. Transmural, haemorrhagic myocardial infarction after intracoronary streptokinase: Clinical, angiographic, and necropsy findings. Br Heart J. 1982;48:546–551.